EP. 122 - As COVID-19 continues to evolve, it is essential to consider vaccine options that provide a broad immune response against a range of variants.

The Novavax COVID-19 Vaccine uses protein-based technology similar to technologies used in vaccines to protect against Hepatitis B, Flu and Whooping Cough. Now available in all 50 states, the two-dose primary series has received Emergency Use Authorization (EUA) for ages 12+ and is also currently under review by the FDA for use as a booster.

Novavax Executive Vice President & Chief Communications Officer Silvia Taylor joined me to share more information.

Please subscribe and rate our show!